ABCG1公司
ABCA1
胆固醇
转基因小鼠
桥甾醇
内分泌学
拉托斯特罗尔
内科学
载脂蛋白E
羊毛甾醇
转基因
生物
脂蛋白
甾醇
内生
化学
生物化学
喜树酯
医学
运输机
基因
疾病
作者
Braydon L. Burgess,Kathryn E. Naus,Jeniffer Y. Chan,Veronica Hirsch‐Reinshagen,Gavin Tansley,Lisa Matzke,Benny Chan,Anna Wilkinson,Jianjia Fan,James J. Donkin,Danielle Balik,Tracie Tanaka,George Ou,Roger Dyer,Sheila Margaret Innis,Bruce M. McManus,Dieter Lütjohann,Cheryl Lea Wellington
标识
DOI:10.1161/atvbaha.108.168542
摘要
OBJECTIVE: The purpose of this study was to evaluate the effects of whole body overexpression of human ABCG1 on atherosclerosis in apoE(-/-) mice. METHODS AND RESULTS: We generated BAC transgenic mice in which human ABCG1 is expressed from endogenous regulatory signals, leading to a 3- to 7-fold increase in ABCG1 protein across various tissues. Although the ABCG1 BAC transgene rescued lung lipid accumulation in ABCG1(-/-) mice, it did not affect plasma lipid levels, macrophage cholesterol efflux to HDL, atherosclerotic lesion area in apoE(-/-) mice, or levels of tissue cholesterol, cholesterol ester, phospholipids, or triglycerides. Subtle changes in sterol biosynthetic intermediate levels were observed in liver, with chow-fed ABCG1 BAC Tg mice showing a nonsignificant trend toward decreased levels of lathosterol, lanosterol, and desmosterol, and fat-fed mice exhibiting significantly elevated levels of each intermediate. These changes were insufficient to alter ABCA1 expression in liver. CONCLUSIONS: Transgenic human ABCG1 does not influence atherosclerosis in apoE(-/-) mice but may participate in the regulation of tissue cholesterol biosynthesis.
科研通智能强力驱动
Strongly Powered by AbleSci AI